Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The purpose of the study is to determine the beneficial effects of CBX129801 (PEGylated synthetic human C-peptide) following weekly subcutaneous administration for 12 months in type 1 diabetes mellitus patients (T1DM) with mild to moderate diabetic peripheral neuropathy (DPN).
Epistemonikos ID: 3bcff4618041b9fec4b61858c021d9a9c6755175
First added on: May 11, 2024